Xynomic Buys Rights to Boehringer's Phase II Ready mTORC1/2 Inhibitor
US-China biopharma is paying up to $800m to Boehringer Ingelheim in connection with in-licensing BI 860585, its second asset purchase from the German big pharma.
You may also be interested in...
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.